Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
=== Aftermath === Sunny's family remained convinced that her husband had tried to murder her and was upset that Cosima had chosen to take her father's side. As a result, in 1981, Sunny's mother, Annie Laurie Aitken, disinherited Cosima, denying her share of the estate upon Aitken's death on May 4, 1984. In July 1985, ten days after Claus von Bülow was acquitted at his second trial, Ala and Alexander filed a $56 million civil lawsuit against him, on their mother's behalf. On December 24, 1987, this case was settled out of court when Claus von Bülow agreed to divorce her, give up all claims to her fortune, then estimated between $25 million and $40 million, and leave the country. In exchange, Cosima was reinstated in Aitken's will and received $30 million as her one-third share of the estate. After the trials, Ala and Alexander founded the Sunny von Bülow National Victim Advocacy Center in Fort Worth, Texas, now the National Center for Victims of Crime in Washington, DC, and the Sunny von Bülow Coma and Head Trauma Research Foundation in New York.
The results are clear cut, and show that penicillin is active in vivo against at least three of the organisms inhibited in vitro. It would seem a reasonable hope that all organisms in high dilution in vitro will be found to be dealt with in vivo. Penicillin does not appear to be related to any chemotherapeutic substance at present in use and is particularly remarkable for its activity against the anaerobic organisms associated with gas gangrene. The publication attracted little attention; Florey would spend much of the next two years attempting to convince people of the significance of their results. One reader was Fleming, who paid them a visit on 2 September 1940. Florey and Chain gave him a tour of the production, extraction and testing laboratories, but he made no comment and did not congratulate them on the work they had done. Some members of the Oxford team suspected that he was trying to claim some credit for it. Unbeknown to the Oxford team, their Lancet article was read by Martin Henry Dawson, Gladys Hobby and Karl Meyer at Columbia University, and they were inspired to replicate the Oxford team's results. They obtained a culture of Penicillium mould from Roger Reid at Johns Hopkins Hospital, grown from a sample he had received from Fleming in 1935. They began growing the mould on 23 September, and on 30 September tested it against viridans streptococci, and confirmed the Oxford team's results. Meyer duplicated Chain's processes, and they obtained a small quantity of penicillin.
== History == In 1976, the first Old Chicago taphouse opened in Boulder, Colorado. The first Gordon Biersch Brewery Restaurant was opened in Palo Alto, California on July 6, 1988. The first Rock Bottom restaurant opened in Denver, Colorado in 1991. In 1993, Big River Breweries opened its first location in Chattanooga, Tennessee. Rock Bottom Restaurants, Inc., made an initial public offering in 1994. In 1995, the first ChopHouse opened in Denver, Colorado. Big River Breweries opened the only brewpub at Walt Disney World in 1996. A private management buyout took Rock Bottom Restaurants, Inc. private in 1999. In the same year, Gordon Biersch was acquired by Big River Breweries. In 2000, Rock Bottom Restaurants formed the Rock Bottom Foundation, a 501(c)(3) non-profit entity. Rock Bottom Restaurants laid off about 20% of its corporate staff in 2007 and slowed its growth plans along with ceasing its search for an equity partner. In 2010, Rock Bottom Restaurants and Gordon Biersch Brewery Restaurant Group were acquired by Centerbridge Capital Partners and merged to form CraftWorks Restaurants and Breweries, Inc. On November 1, 2018, CraftWorks announced that it had acquired Logan's Roadhouse and formed Craftworks Holdings. Logan's Roadhouse is a chain of restaurants founded in 1991 in Lexington, Kentucky. The chain's menu includes mesquite-grilled steaks, traditional American fare (sandwiches, soup, salads, and seafood), ice-cold longneck beer, and homemade yeast rolls. On June 12, 2020, Craftworks was purchased by SPB Hospitality for $93 million.
Sources: en.wikipedia.org
June 18 Iran war: Primary mediator Pakistan states that the signing of the US-Iran memorandum of understanding to end the war implies Tehran will reopen the Hormuz "instantly" and the American blockade of Iranian ports will end "immediately." MV Hondius hantavirus outbreak: Two more passengers who were on the MV Hondius cruise ship during the hantavirus outbreak exit the National Quarantine Unit at the University of Nebraska Medical Center in Omaha, Nebraska, bringing the total number of people remaining in quarantine to six. After over 35 years in service, the U.S. Air Force retires the Boeing VC-25A aircraft used as Air Force One. The Barack Obama Presidential Center is dedicated in Chicago, with all living former presidents except Trump in attendance. June 19 Trump officially unveils the Qatari-gifted Air Force One at Joint Base Andrews. The Department of Justice opens an investigation into Major League Baseball (MLB) after the league warned three San Francisco Giants players for writing Bible verses over their rainbow logo caps before a Pride Night game. June 21 Iran war: Trump issues a threat to invade Iran if they close the Strait of Hormuz, following Iran's claim of its closure due to Israeli strikes in Lebanon. He warns that they "won't even make it back to their fucking country," suggesting a potential threat against Iranian negotiators in Switzerland.
5-Oxo-ETE and 5-oxo-15(S)-hydroxy-ETE but not 5-hydroxy members of the 5-HETE family such as 5-(S)-HETE activate peroxisome proliferator-activated receptor gamma (PPARγ). This activation does not proceed through OXER1; rather, it involves the direct binding of the oxo analog to PPARγ with 5-oxo-15-(S)-hydroxy-ETE being more potent than 5-oxo-ETE in binding and activating PPARγ. The Activation of OXER1 receptor and PPARγ by the oxo analogs can have opposing effects on cell function. For example, 5-oxo-ETE-bound OXER1 stimulates whereas 5-oxo-ETE-bound PPARγ inhibits the proliferation of various types of human cancer cell lines; this results in 5-oxo-ETE and 5-oxo-15-(S)-HETE having considerably less potency than anticipated in stimulating these cancer cells to proliferate relative to the potency of 5-(S)-HETE, a relationship not closely following the potencies of these three compounds in activating OXER1. 5-Oxo-ETE relaxes pre-contracted human bronchi by a mechanism that does not appear to involve OXER1 but is otherwise undefined.
The fragment molecular orbital method (FMO) was developed by Kazuo Kitaura and coworkers in 1999. FMO is deeply interconnected with the energy decomposition analysis (EDA) by Kazuo Kitaura and Keiji Morokuma, developed in 1976. The main use of FMO is to compute very large molecular systems by dividing them into fragments and performing ab initio or density functional quantum-mechanical calculations of fragments and their dimers, whereby the Coulomb field from the whole system is included. The latter feature allows fragment calculations without using caps. The mutually consistent field (MCF) method had introduced the idea of self-consistent fragment calculations in their embedding potential, which was later used with some modifications in various methods including FMO. There had been other methods related to FMO including the incremental correlation method by H. Stoll (1992). Later, other methods closely related to FMO were proposed including the kernel energy method of L. Huang and the electrostatically embedded many-body expansion by E. Dahlke, S. Hirata and later M. Kamiya suggested approaches also very closely related to FMO. Effective fragment molecular orbital (EFMO) method combines some features of the effective fragment potentials (EFP) and FMO. A detailed perspective on the fragment-based method development can be found in a review.
A blood glucose meter is an electronic device for measuring the blood glucose level. A relatively small drop of blood is placed on a disposable test strip which interfaces with a digital meter. Within several seconds, the level of blood glucose will be shown on the digital display. Needing only a small drop of blood for the meter means that the time and effort required for testing are reduced and the compliance of diabetic people to their testing regimens is improved significantly. Blood glucose meters provide results in various units such as eAG (mg/dL) and eAG (mmol/L), and may also estimate A1C levels. These measurements can aid in classifying blood glucose levels as normal, prediabetic, or diabetic, facilitating effective diabetes management for users. While some models offer interpretative features that indicate the health status based on these results, not all meters provide this functionality, focusing instead on providing raw glucose measurements. Users of blood glucose meters without interpretative features can utilize online calculators to determine their blood glucose status based on measured values. The cost of using blood glucose meters is believed to be a cost-benefit relative to the avoided medical costs of the complications of diabetes. Recent advances include:
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.